Department of Otorhinolaryngology Head and Neck Surgery, Integrated Centre for Balance Disorders, Grosshadern Medical Centre, University of Munich, Marchioninistr. 15, 81377 Munich, Germany.
Eur Arch Otorhinolaryngol. 2013 Mar;270(4):1231-5. doi: 10.1007/s00405-012-2087-3. Epub 2012 Jul 4.
This study aimed to assess whether standard-dose Betahistine (48 mg daily) exerts an effect upon the degree of endolymphatic hydrops in patients with Menière's disease using a retrospective case series in the setting of a tertiary neurotology referral centre. In six patients with definite unilateral Menière's disease, the degree of cochlear and vestibular endolymphatic hydrops was assessed before and after treatment with a standard dose of Betahistine (48 mg daily), using high-resolution 3 T MR imaging after intratympanic contrast medium application. The treatment duration was 3-7 months (mean 5 months), and the patients were followed-up for 6-29 months (mean 11 months). In the study cohort, the standard dose of Betahistine did not have an MR morphologically measurable beneficial effect on the degree of endolymphatic hydrops. The results indicated no effect of standard-dose Betahistine on endolymphatic hydrops found on high-resolution MR imaging. Possible explanations are: (1) insufficient dosage or duration of treatment with betahistine, (2) insufficient resolution of the MR imaging technique, and (3) insufficient length of follow-up. Further studies addressing these issues are warranted.
本研究旨在评估标准剂量倍他司汀（每日 48 毫克）是否会通过在三级神经耳科学转诊中心的回顾性病例系列中对梅尼埃病患者的内淋巴积水程度产生影响。在 6 名单侧梅尼埃病确诊患者中，在使用鼓室内对比剂后，使用高分辨率 3T MR 成像，评估标准剂量倍他司汀（每日 48 毫克）治疗前后的耳蜗和前庭内淋巴积水程度。治疗持续时间为 3-7 个月（平均 5 个月），患者随访时间为 6-29 个月（平均 11 个月）。在研究队列中，标准剂量的倍他司汀对内淋巴积水程度没有 MR 形态学上可测量的有益作用。结果表明，高分辨率 MR 成像上未见标准剂量倍他司汀对内淋巴积水的影响。可能的解释有：（1）倍他司汀的剂量或治疗时间不足，（2）MR 成像技术的分辨率不足，（3）随访时间不足。需要进一步研究这些问题。
